G22恒峰(中国)

专注给予质高价优

科学论文

A novel anti-CD3xCD28xSTEAP1 trispecific T-cell engager (HLX3902) with enhanced and durable antitumor responses in prostate cancer
AACR 2026
A Best-in-Class HER2xHER2 Novel Biparatopic Antibody-Drug Conjugate with an Efficacious, Low-Toxicity Design that Maximizes Antibody Functionality
AACR 2026
Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9
AACR 2026
Development of a first-in-class camptothecin-based antibody-drug conjugate targeting ALPP/ALPPL2 with potent antitumor activity and excellent tolerability
AACR 2026
Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class cMet/EGFR bispecific antibody-drug conjugate
AACR 2026
Preclinical Studies Reveal that Protease-Mediated Payload Release and Immuno-Oncology/Immunomodulatory Effects Contribute to the Antitumor Activity of HLX43
AACR 2026

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97